Patrick Gallagher

Aerwave Medical, Inc. is a company that is developing a unique alternative to traditional medications used to treat pulmonary diseases such as asthma and COPD. The company is based in New York, NY, and the CEO of the company is Jeffrey Francis O'Donnell. These diseases are characterized by an unmet medical need, with up to 15% of asthma patients and 25% of COPD patients being unresponsive to treatment. Additionally, around 50% of long-term inhaler users discontinue use within the first year due to compliance issues and multiple side effects. Aerwave Medical's revolutionary approach involves an interventional method to treat these diseases.

Cingulate Therapeutics LLC operates as a biopharmaceutical company. It focuses on the development of new products for the treatment of central nervous system and neurobiological disorders. The company was founded by Shane J. Schaffer, Patrick Joseph Gallagher, Matthew Brams, Arthur B. Sthraughn, Craig S. Gilgallon and Raul R. Silva and is headquartered in Kansas City, KS.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Cingulate Therapeutics LLC operates as a biopharmaceutical company. It focuses on the development of new products for the treatment of central nervous system and neurobiological disorders. The company was founded by Shane J. Schaffer, Patrick Joseph Gallagher, Matthew Brams, Arthur B. Sthraughn, Craig S. Gilgallon and Raul R. Silva and is headquartered in Kansas City, KS.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Cingulate Therapeutics LLC operates as a biopharmaceutical company. It focuses on the development of new products for the treatment of central nervous system and neurobiological disorders. The company was founded by Shane J. Schaffer, Patrick Joseph Gallagher, Matthew Brams, Arthur B. Sthraughn, Craig S. Gilgallon and Raul R. Silva and is headquartered in Kansas City, KS.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Laidlaw Venture Partners (Laidlaw Venture) is a venture capital subsidiary of Laidlaw & Co(UK) Ltd. The firm is headquartered in New York.

Voltron Therapeutics, Inc. develops the vaccine and immunotherapy center. The company was founded in 2017 and is headquartered in New York, NY.

Cingulate Therapeutics LLC operates as a biopharmaceutical company. It focuses on the development of new products for the treatment of central nervous system and neurobiological disorders. The company was founded by Shane J. Schaffer, Patrick Joseph Gallagher, Matthew Brams, Arthur B. Sthraughn, Craig S. Gilgallon and Raul R. Silva and is headquartered in Kansas City, KS.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Voltron Therapeutics, Inc. develops the vaccine and immunotherapy center. The company was founded in 2017 and is headquartered in New York, NY.

Voltron Therapeutics, Inc. develops the vaccine and immunotherapy center. The company was founded in 2017 and is headquartered in New York, NY.

Laidlaw Venture Partners (Laidlaw Venture) is a venture capital subsidiary of Laidlaw & Co(UK) Ltd. The firm is headquartered in New York.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Voltron Therapeutics, Inc. develops the vaccine and immunotherapy center. The company was founded in 2017 and is headquartered in New York, NY.

Part of Laidlaw Holdings Ltd., Laidlaw & Co. (UK) Ltd. is a British company that provides investment advice. The private company is based in London, UK. The company was founded in 1842. Matthew D. Eitner has been the CEO of the company since 2010.

Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS.

Cingulate Therapeutics LLC operates as a biopharmaceutical company. It focuses on the development of new products for the treatment of central nervous system and neurobiological disorders. The company was founded by Shane J. Schaffer, Patrick Joseph Gallagher, Matthew Brams, Arthur B. Sthraughn, Craig S. Gilgallon and Raul R. Silva and is headquartered in Kansas City, KS.

Laidlaw Venture Partners (Laidlaw Venture) is a venture capital subsidiary of Laidlaw & Co(UK) Ltd. The firm is headquartered in New York.

Cowen Prime Services LLC (CPS) is a broker-dealer headquartered in New York City. The firm is directly owned by Cowen PB Holdings LLC, which, in turn, is primarily owned by Cowen Group, Inc. (NASDAQ: COWN). CPS is registered as a broker-dealer with the SEC and FINRA, and as a an introducing broker with the Commodities Futures Trading Commission and the National Futures Association. CPS was formed in 2015 following Cowen Group’s acquisition of Concept Capital Markets LLC. Concept Capital was established in 2010 following the spin-off of the Concept Capital division of Sanders Morris Harris Inc., whose origins date back to 1995. CPS' offering includes world-class custody and clearing options, multi asset class capabilities, leading execution and order management systems, a seasoned execution desk, a range of financing options, a highly professional operations and customer support team, comprehensive portfolio reporting capabilities, capital introduction, and live, intraday and post-trade risk and performance analytics.

Cowen Prime Services LLC (CPS) is a broker-dealer headquartered in New York City. The firm is directly owned by Cowen PB Holdings LLC, which, in turn, is primarily owned by Cowen Group, Inc. (NASDAQ: COWN). CPS is registered as a broker-dealer with the SEC and FINRA, and as a an introducing broker with the Commodities Futures Trading Commission and the National Futures Association. CPS was formed in 2015 following Cowen Group’s acquisition of Concept Capital Markets LLC. Concept Capital was established in 2010 following the spin-off of the Concept Capital division of Sanders Morris Harris Inc., whose origins date back to 1995. CPS' offering includes world-class custody and clearing options, multi asset class capabilities, leading execution and order management systems, a seasoned execution desk, a range of financing options, a highly professional operations and customer support team, comprehensive portfolio reporting capabilities, capital introduction, and live, intraday and post-trade risk and performance analytics.

Laidlaw Venture Partners (Laidlaw Venture) is a venture capital subsidiary of Laidlaw & Co(UK) Ltd. The firm is headquartered in New York.

Part of Laidlaw Holdings Ltd., Laidlaw & Co. (UK) Ltd. is a British company that provides investment advice. The private company is based in London, UK. The company was founded in 1842. Matthew D. Eitner has been the CEO of the company since 2010.